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g.2012.0Abstract The mitochondrial DNA depletion syndromes are autosomal recessive disorders character-
ized by decreased mitochondrial DNA copy number in affected tissues. Mutations in 2 genes involved
in deoxyribonucleotide metabolism, the deoxyguanosine kinase gene and the thymidine kinase 2 gene,
had been related to this syndrome. This study aims to describe the clinical, histochemical, biochemical
and molecular diagnosis of one Egyptian pediatric patient with the myopathic form of mitochondrial
depletion syndrome. The patient presented to Cairo University Pediatric Hospital with the clinical sus-
picion of mitochondrial encephalomyopathy. Histochemical and biochemical studies of the respiratory
chain complexes were performed on the muscle biopsy specimen from the patient. Molecular diagnosis
was done by quantitative radioactive Southern blot and sequencing analysis of thewhole coding regions
of the TK2 gene. Histochemical staining revealed cytochrome oxidase negative ﬁbers and increased
staining for succinate dehydrogenase. The activity of complex I was not detected and complex IV activ-
ity was about 46% of age matched controls. Southern blot analysis showed reduction of the mitochon-
drial/nuclear DNA ratio, the degree of depletion was around 30% of aged-matched controls.
Sequencing analysis of the TK2 gene revealed no sequence variation. Targeted molecular diagnosis
based on the biochemical analysis of the respiratory chain enzymes makes the molecular evaluation
of mitochondrial disorders much easier. Involvement of other nuclear genes rather than TK2 gene in
the pathogenesis of the myopathic form of mitochondrial depletion syndrome should be considered.
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352 L. Selim et al.1. Introduction
Mitochondria are keys to many cellular processes. One of the
most important mechanisms is oxidative phosphorylation
(OXPHOS) resulting in the production of cellular energy in
the form of ATP. The OXPHOS system consists of ﬁve com-
plexes (I–V) and two mobile electron carriers (coenzyme Q
and cytochrome c) embedded in the inner mitochondrial mem-
brane [1].
The mitochondrial genome encodes 13 essential polypep-
tides of the OXPHOS system and the necessary RNAs machin-
ery. The remaining structural proteins and those involved in
import, assembly and mitochondrial DNA (mtDNA) replica-
tion are encoded by the nuclear DNA and are targeted to
the mitochondria [2].
Disorders of mitochondrial origin are a heterogeneous
group of diseases commonly manifesting in tissues with a
high-energy demand, for example, muscle and nerve, hence
the name ‘‘mitochondrial encephalomyopathies’’ [3].
Mutations in respiratory chain protein subunits encoded by
either mitochondrial (mt) DNA or nuclear (n) DNA are
responsible for such diseases [4]. Over 100 point mutations
of mtDNA that are known to cause mitochondrial dysfunction
had been identiﬁed [5].
Recent developments in the molecular diagnostics allowed
for the exploration of many of pathogenic mutations, thus pro-
viding more clues about the molecular basis of these disorders.
The aim of the present study is to describe the clinical, histo-
chemical, biochemical and molecular diagnosis of one Egyptian
pediatric patient with the myopathic form of mitochondrial
DNA depletion syndrome.
2. Case report
A 2.5 years old girl, the 3rd child of unrelated parents, born by
a caesarean section at term after normal pregnancy. She hadFigure 1 MRI brain of the proband showing abnormal T2 and F
aqueductal gray matter (2), medulla oblongata (3) and lower pons (4)normal developmental history. By the age of 1.5 years, mother
noticed unsteadiness of gait and repeated falling followed at
2 years by loosing the ability of independent walking, with
the appearance of head nodding, nystagmus and squint fol-
lowed by seizures. Her clinical examination revealed ataxia
and generalized trunkal and limb hypotonia, bilateral ptosis,
external ophthalmoplegia and ﬁne nystagmoid movements.
Her laboratory investigations showed persistent lactic acide-
mia, 2.8 mmol/L (normal, up to 2.2 mmol/L). Liver and kid-
ney functions, creatine kinase (CK) and plasma ammonia
were normal. Brain magnetic resonance imaging (MRI)
showed abnormal lesions in the basal ganglia (appearing hyp-
odense in T1 weighted images (WIs) and hyperintense on T2
WIs, cerebellar demylination and abnormal signal intensity
in the brain stem. This picture was suggestive of SURF1 gene
mutation Fig. 1. Echocardiographic (ECHO) and chest radio-
graphic ﬁndings were normal. An electroencephalogram
(EEG) showed epileptiform activity. The parents have one
healthy daughter (1 year old). Their ﬁrst child (III-1) had pre-
sented in a similar manner at 8 months of age and died by the
age of 2.5 years, the cause of death was uncertain. They had a
boy (III-2) who died by 32 weeks of gestation (S.B.) Fig. 2.
3. Methods
3.1. Ethical issue
Verbal consent was obtained from the parents for all the pro-
cedures performed. Parental written informed consent was ob-
tained for the undergoing muscle biopsy.
3.2. Family history
The patient who is a regular visitor of the neurometabolic
clinic of Cairo University Pediatric Hospital (CUPH) pre-
sented clinically with encephalomyopathy. The underlyingLAIR hyperintense signals are noted at: dentate nuclei (1), peri-
(arrows).
Table 1 Sequence of the primers used for ampliﬁcation and
sequencing of ATPase 6 gene.
PCR primers Sequence (50–30)
MTF8200 TTTCATGCCCATCGTCCTAGAATTA
MTR9550 TGCCCTCCTAATTGGGGGGTA
MTF 8648 GACTAATCACCACCCAACAATGAC
Figure 2 Family pedigree of the studied patient.
Mitochondrial DNA depletion syndrome presenting with ataxia and external ophthalmoplegia: Case report 353cause of encephalomyopathy was suspected clinically to be of
mitochondrial origin. Members of the family pedigree were
interviewed to identify both personal or family medical histo-
ries and other clinical abnormalities.
3.3. Muscle biopsy
Muscle biopsy specimens from Quadriceps Femoris were per-
formed under general anesthesia at the CUPH. The specimens
were immediately frozen in liquid nitrogen after collection,
stored at 80 C.
3.4. Histochemical and biochemical investigations
The activities of the respiratory chain (RC) complexes and
the Citrate Synthase (CS) as a marker for the mitochondrialFigure 3 Histochemical analysis of the muscle biopsy of the proband
reduced enzymatic activity in several myoﬁbers (for both, the magniﬁc
are highly suggestive of mitochondrial disease.content, were determined in the muscle homogenate using
standard spectrophotometric methods [6,7]. Enzyme activities
are expressed with respect to both the total protein and CS
activity [8]. Muscle biopsy specimens were subjected to histo-
chemical staining for COX and SDH using Bio-Optica Stain-
ing Kits; Milan, Italy.
3.5. Molecular genetic studies
Total nuclear DNA and mtDNA were extracted from periph-
eral blood leukocytes of the patient along with age and sex
matched healthy controls. The control pediatric group was
attending the hospital for other different reasons. All control
subjects reported no symptomatic metabolic, genetic or ocular
disorders regarding family history, past medical problems and
current health. Extraction was done using the DNA isolation
kit from Qiagen (TM), Germany, following the manufacturer’s
instructions. DNA was extracted from the muscle biopsy spec-
imens of the proband along with other age-matched patients
and controls using the phenol–chlorophorm–isoamyl alcohol
method, according to the published methods [9–12].
As neuroimaging of the proband was initially suggestive of
the mitochondrial disorder, Leigh syndrome, ATPase 6 gene
was examined by direct sequencing being commonly mutated
in such disorder [13]. The gene was PCR-ampliﬁed from blood
DNA using the forward and reverse primers MTF8200 and
MTR9550 respectively. The puriﬁed products were sequenced
by the Applied Biosystems (ABI) 3130xl genetic analyzer using
the capillary electrophoresis. The MTF8200, MTF 8648 and
MTR9550 primers were used for sequencing (Table 1). The se-
quences were analyzed using Staden software. Sequencing re-
sults were compared with the revised Cambridge reference
sequence (rCRS) [14]. All sequence variants were compared
with the MITOMAP database (http://www.mitomap.org), the
Human Mitochondrial Genome Database (http://www.gen-
pat.uu.se/mtDB) and the GiiB-JST mtSNP (single nucleotide
polymorphism) database (http://mtsnp.tmig.or.jp/mtsnp/in-
dex_e.shtml), all are provided in the public domain.
Based on the clinical suspicion ofmitochondrial DNAdeple-
tion syndromes (MDS) and according to the histochemical and. (A) SDH stain shows increased staining, (B) COX staining shows
ation ·40) (arrows). Increased SDH stain and reduced COX stain
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354 L. Selim et al.biochemical analyses results, P32-radioactive Southern blot and
quantitation of the mt/n DNA ratio were conducted as previ-
ously described [15,16]. For conﬁrmation of themyopathic form
of MDS, TK2 gene was sequenced using the 3130xl ABI auto-
mated sequencer [17].4. Results
Results of histochemical staining of the muscle biopsy speci-
men were compatible with mitochondrial myopathy. There
was increased staining for SDH Fig. 3A and COX negative ﬁ-
bers Fig. 3B. The SDH stain evaluates complex II of the RC
(totally encoded by the nuclear DNA) while [18], the COX
stain evaluates complex IV [19] encoded for by both n/mt
DNA. The presence of increased SDH activity and decreased
COX activity is highly suggestive of mtDNA involvement
[20,21].
Biochemical analysis of the muscle biopsy specimen was
suggestive of mtDNA involvement. Marked reduction of the
activities of the RC complexes had been detected. Complex ITable 3 Nucleotide changes found in ATPase 6 genes.
Nucleotide
locus
Nucleotide
position (a)
Sequence
change
Amino acid
change (b)
Previously
reported references
ATPase 6 8292 g-a Non-coding [22]
ATPase 6 8527 a-g M-V [23]
ATPase 6 8723 g-a R-Q [24]
(a) Changes at the following nucleotides positions are frequently
occurring variants in the general population. (b) The ﬁrst letter is
the amino acid residue predicted by the revised Cambridge
sequence. The last letter is the predicted amino acid in the protein of
the patient. Amino acid changes are expressed as one letter code:
http://molbio.info.nih.gov/gcode.html.
Table 4 Quantitation of mt/n DNA ratio of the proband and
other myopathic patients (2–6) along with control cases using
phosphorus imager. The results are expressed as the copy
number of mitochondrial DNA per haploid nuclear gene. The
control value of the muscle mtDNA copy number was obtained
through the pooling of muscle specimens of 9 age-matched
controls (1–9). The degree of depletion in the proband of the
present study was around 50% of age-matched controls.
mtDNA/nDNA ratio
7.916940226 CONTROL 1 CONTROLS
6.497194225 CONTROL 2
6.697378218 CONTROL 3 Mean: Std. Dev.:
6.716325279 CONTROL 4 5865 1245
6.158424718 CONTROL 5 Minimum: Maximum:
4.197091359 CONTROL 6 4197 7917
5.256952307 CONTROL 7
4.291275294 CONTROL 8
5.051666402 CONTROL 9
2.958601912 The proband (1) PATIENTS
3.59282748 PATIENT2
3.47408944 PATIENT3 Mean: Std. Dev.:
3.347482147 PATIENT4 3228 0.285
2.900524709 PATIENT5 Minimum: Maximum:
3.096489032 PATIENT6 2901 3593
Figure 4 Autoradiograph of Southern blot of total DNA
extracted from muscle of the proband. The total (nuclear and
mitochondrial) DNA was hybridized simultaneously with two 32P-
labeled probes––human mtDNA and a cloned fragment of the
human 18S ribosomal RNA gene (nuclear DNA). Arrows.
Mitochondrial DNA depletion syndrome presenting with ataxia and external ophthalmoplegia: Case report 355activity was not detected. Complex IV activity was about 46%
of age-matched healthy controls. The activities were also found
to be reduced when referred to CS. Activity of SDH was nor-
mal. Results of biochemical analysis are shown in Table 2.
Sequencing analysis of the ATPase 6 gene revealed 3 recog-
nized benign polymorphisms [22–24] Table 3. Southern blot
analysis showed reduction of the mt/n DNA ratio of the stud-
ied case and conﬁrmed mitochondrial DNA depletion, the de-
gree of depletion was around 50% of age-matched controls
Table 4, Fig. 4. Sequencing analysis of the TK2 gene revealed
no sequence variations.
5. Discussion
Mitochondrial DNA depletion syndromes (MDS) are autoso-
mal recessive disorders characterized by a reduction in mito-
chondrial DNA copy number in the clinically affected tissues
[4,15].
A balanced supply of deoxyribonucleoside triphosphates
(DNTPs) is required for DNA polymerase c to faithfully rep-
licate the mitochondrial genome, the mitochondrial deoxynu-
cleotide triphosphates (dNTPs) pool is maintained both
through the import of cytosolic dNTPs and by salvaging
deoxyribonucleosides within the organelle itself [4,25].
A number of nuclear-encoded enzymes are involved in these
processes, including thymidine kinase 1 (TK1) within the cyto-
sol, thymidine kinase 2 (TK2) and deoxyguanosine kinase
(dGK) within mitochondria. The last two are key enzymes of
the mitochondrial salvage pathway [4,26].
In the past few years, there had been a substantial increase
in the understanding of the molecular basis of mtDNA deple-
tion syndromes [8]. The TK2 gene is located on chromosome
16 and encodes a 234-amino acid polypeptide, which is synthe-
sized in the cytoplasm, then imported into the mitochondrial
matrix [20]. It catalyzes the transfer of a phosphate group from
adenosine triphosphate to thymidine or deoxycytidine [28,29],
whereas dGK efﬁciently phosphorylates deoxyguanosine and
deoxyadenosine to the corresponding deoxynucleotide mono-
phosphates [30]. The combined action of the 2 enzymes allows
the synthesis of all 4 dNTPs needed for mtDNA replication
[30,31].Mutations in the TK2 gene in patients with myopathic
MDS [28] and mutations in the dGK gene in patients with
hepatocerebral MDS [32,33] were identiﬁed conﬁrming the
concept that imbalances in mitochondrial dNTP pool can
affect mtDNA integrity. This imbalance leads to inefﬁcient
replication and, therefore, depletion of mtDNA [18,34]. More
recently, mutations in RRM2B, encoding the small subunit of
p53-inducible ribonucleotide reductase, have also been identi-
ﬁed in patients with myopathic mtDNA depletion disorder
[35].
The MDS differs from other mitochondrial disorders be-
cause it is a quantitative defect rather than a qualitative defect.
The low level of mtDNA in some tissues causes insufﬁcient
synthesis of respiratory chain components [15]. Depletion of
mtDNA can occur as a secondary phenomenon, for example
as a result of antiretroviral nucleoside analogue therapy [36].
In MDS, however, mtDNA depletion is considered a primary
process, and the degree of depletion is generally proportional
to the severity of the phenotype [27].
Patients with the myopathic form of MDS usually present
at or soon after birth with progressive weakness, hypotonia,
hyporeﬂexia, and die of respiratory failure before 1 year of
age (congenital form) or before 10 years of age (juvenile form)
[27].
Since the ﬁrst description of TK2 mutations leading to the
myopathic form of mtDNA depletion syndrome in 2001,
approximately 20 different pathogenic mutations have now
been reported, distributed throughout the TK2 coding se-
quence [37].
The proband of the present study was clinically suspected
to have mitochondrial encephalomyopathy. Based on MRI
ﬁndings, the initial diagnosis was suggestive of Leigh syndrome
(LS) with SURF1 gene mutation. Bilateral putaminal T2 pro-
longation has long been considered a consistent feature of LS
on MRI studies [38]. LS with COX deﬁciency caused by
SURF1 gene mutations represents a relatively homogeneous
clinical entity. Similar to the proband of this study, affected
patients present at around 1 year of age with progressive
encephalopathy, generalized hypotonia, trunk ataxia, oculo-
motor abnormalities and central respiratory problems
[39,40]. However, the biochemical evidence of deﬁciency of
complex I and complex IV in such case was against the sugges-
tion of SURF1 gene mutation which is exclusively associated
with isolated complex IV deﬁciency.
As high index of suspicion of MDS is warranted in any
child with proximal weakness and hypotonia of unclear etiol-
ogy, the diagnosis needed to be conﬁrmed by Southern blot
analysis for mtDNA quantitation and subsequent TK2 muta-
tion screening [37].
Based on the results of histochemical, biochemical and
molecular analyses, the proband had fulﬁlled the diagnostic
criteria for the myopathic form of MDS [41,42]. These criteria
include clear evidence of mtDNA depletion by Southern blot,
histochemical evidence of COX deﬁciency, plus at least two of
the following features: ragged-red ﬁbers (RRF), lactic acidosis,
multiple defects of respiratory chain enzymes [25]. Based on
these ﬁndings, it was mandatory to screen this patient for
mutations in TK2 gene, in order to better deﬁne the frequency
of mutations in this gene.
Similar studies had been conducted by Tiranti et al., Johans-
son et al., Mandel et al. and Finsterer [4,25,37,43]. Similar to
the probands of the present study, those patients developed
356 L. Selim et al.myopathy and depletion of muscular mtDNA in infancy. In
contrast to results of the present study, several mutations in
TK2 gene had been detected conﬁrming the hypothesis that
mutations in TK2 represent a new etiology for mitochondrial
DNA depletion, underscoring the importance of the mitochon-
drial dNTP pool in the pathogenesis of mitochondrial deple-
tion. Therefore, MDS should be included in the differential
diagnosis of all unexplained myopathies of infancy and child-
hood [27,44].
Similar to the conclusion of the present study, it had been
found that the myopathic form of MDS is genetically heteroge-
neous. TK2 mutations account for only a small percentage of
patients with the myopathic form of MDS [25]. This suggests
that defects in other genes must be involved in the etiology of
myopathic MDS. Therefore, it is recommended to screen nega-
tive patients for mutations in other candidate genes rather than
TK2 and dGK genes involved in dNTP metabolism.
The CK level of the proband of the present study was nor-
mal. Similar ﬁnding had been found in a study that involved
4 patients with MDS [37]. Similarly, they concluded that
marked increase in serum CK values seen in most patients is
an unusual ﬁnding in mitochondrial myopathies and a useful
diagnostic clue.
6. Conclusion
Holistic approach through clinical, neuroimaging, histochemi-
cal, biochemical and molecular investigations is important to
reach the ﬁnal diagnosis. Targeted molecular diagnosis based
on the biochemical analysis of RC enzymes makes the molecu-
lar evaluation of pediatric mitochondrial disorders more easier.
Negative results of molecular diagnosis for mtDNA genes do
not exclude mitochondrial diseases and involvement of nuclear
genes should be always suspected.
To the best of our knowledge, this study is the ﬁrst study
that reported on the Egyptian patient with MDS syndrome
through molecular analysis which further reinforces the funda-
mental role of molecular analysis. Recruitment of the latest
techniques in the molecular genetic analysis of these disorders
can reveal novel mutations. In the future, more information
about the role of molecular genetic analysis will be provided
by large scale family studies and investigation of an increased
number of possible candidate genes identiﬁed by the human
genome project.
Last and not least, Egypt as a country with high consan-
guinity and where genetic disorders are a very common
cause of morbidity and mortality, molecular genetic analysis
including the latest molecular techniques should be highly
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